Fruquintinib approved in U.S., EU, and China for previously treated metastatic CRC

▸ TREATMENT

This oral VEGF receptor inhibitor demonstrated consistent efficacy in two Phase 3 trials: FRESCO (enrolling patients in China) and FRESCO-2 (enrolling patients across 14 countries in North America, Europe, Asia, and Australia), with patients receiving 5 mg once daily on a 3-weeks-on, 1-week-off schedule. (Clin Transl Sci)